ZYAMTIN Trademark

Trademark Overview


On Thursday, May 8, 2025, a trademark application was filed for ZYAMTIN with the United States Patent and Trademark Office. The USPTO has given the ZYAMTIN trademark a serial number of 99175897. The federal status of this trademark filing is REGISTERED as of Tuesday, December 16, 2025. This trademark is owned by uniQure biopharma B.V.. The ZYAMTIN trademark is filed in the Pharmaceutical Products category with the following description:

Biological preparations for medical use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely, vaccines for use in gene therapy; pharmaceutical preparations for the treatment of Dravet's disease, Alzheimer's disease, ALS, Huntington's disease, Fragile X syndrome, Parkinson's disease, A1AT deficiency, epilepsy, temporal lobe epilepsy, focal cortical dysplasia, Fabry disease, multiple system atrophy, spinocerebellar ataxia and dyslipidemia; gene therapy and prophylaxis products, namely, gene-based biological preparations and medical reagents for use in gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, cancer, inflammatory and auto-immune diseases, vascular disorders, and single gene disorders
zyamtin

General Information


Serial Number99175897
Word MarkZYAMTIN
Filing DateThursday, May 8, 2025
Status700 - REGISTERED
Status DateTuesday, December 16, 2025
Registration Number8067143
Registration DateTuesday, December 16, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 28, 2025

Trademark Statements


Goods and ServicesBiological preparations for medical use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely, vaccines for use in gene therapy; pharmaceutical preparations for the treatment of Dravet's disease, Alzheimer's disease, ALS, Huntington's disease, Fragile X syndrome, Parkinson's disease, A1AT deficiency, epilepsy, temporal lobe epilepsy, focal cortical dysplasia, Fabry disease, multiple system atrophy, spinocerebellar ataxia and dyslipidemia; gene therapy and prophylaxis products, namely, gene-based biological preparations and medical reagents for use in gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, cancer, inflammatory and auto-immune diseases, vascular disorders, and single gene disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 8, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameuniQure biopharma B.V.
Party Type30 - Original Registrant
Legal Entity Type26 - NOT AVAILABLE
AddressAmsterdam 1105BP
NL

Party NameuniQure biopharma B.V.
Party Type20 - Owner at Publication
Legal Entity Type26 - NOT AVAILABLE
AddressAmsterdam 1105BP
NL

Party NameuniQure biopharma B.V.
Party Type10 - Original Applicant
Legal Entity Type26 - NOT AVAILABLE
AddressAmsterdam 1105BP
NL

Trademark Events


Event DateEvent Description
Thursday, May 8, 2025NEW APPLICATION ENTERED
Thursday, May 8, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 8, 2025APPLICATION FILING RECEIPT MAILED
Friday, June 20, 2025TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, June 20, 2025TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Wednesday, September 24, 2025ASSIGNED TO EXAMINER
Wednesday, September 24, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 22, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 28, 2025PUBLISHED FOR OPPOSITION
Tuesday, October 28, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 16, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, December 16, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED